Experiencing Hair Loss? This Green Apple Flavored Gummy Could Be What You Need
You've tried the serums, the vitamins and the topical solutions. But have you tried a prescription gummy for hair loss? Hers, a telehealth company that provides online healthcare services and products for women, announced the launch of its Biotin plus Minoxidil Gummy, the first-of-its-kind prescription gummy formulated to support hair regrowth. Available through forhers.com, this gummy combines prescription-strength minoxidil, the only FDA-approved ingredient for female hair loss, with biotin, a popular vitamin for supporting healthy skin, hair and nails. Minoxidil is clinically proven to regrow thicker, fuller hair in three to six months (based on studies of oral minoxidil up to 2.5 mg per day at various doses).
It's the first prescription hair regrowth gummy to hit the market, and it offers women a more convenient way to stay consistent with treatment, something Hers chief medical officer and OB-GYN Dr. Jessica Shepherd says is often overlooked in traditional regimens.
"The gummy is a once-daily dose that's designed to help women stick to their prescribed hair regimens as deemed clinically necessary by their provider to address their individual needs," she says.
Hers
Shepherd told CNET that everything about the product, from the packaging to the vegan formula to the taste (green apple flavor) and texture, was crafted with women's preferences in mind. The goal is a treatment that feels more like a self-care ritual than a chore.
Why a gummy?
Unlike traditional pills or topicals, the Biotin plus Minoxidil Gummy was formulated with adherence in mind. The proprietary compounded formula allows providers to personalize each prescription to individual needs, including adjusting the dosage to minimize side effects or combining multiple ingredients to tackle various concerns simultaneously.
"By leveraging the power of personalization, we're making it possible for women to access treatment designed to address their individual needs for their unique body, lifestyle and goals. This is the benefit of compounding," says Shepherd.
How much does it cost, and where can I get it?
The Biotin plus Minoxidil Gummy is available through Hers after a virtual consultation with one of its licensed providers. Each prescription is customized based on your unique hair loss patterns and goals. Hers strives to offer patients affordable treatments without insurance (no insurance is accepted), and the gummies start at $35 per month.
To learn more or schedule a consultation, visit forhers.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
an hour ago
- CBS News
After her heart started to fail, a first-of-its-kind surgery saved her life
Sue Baker was used to spending time in the hospital. She had started having heart troubles in 2015, and as the issue escalated, she spent more and more time in the hospital. She had a pacemaker implanted to keep her heart beating. Once, she spent five days in a coma. In 2019, as her heart function continued to fail, Baker received a left ventricular assist device, or LVAD, a mechanical pump that helps the heart's left ventricle circulate blood throughout the body. For years, Baker lived on "batteries and electricity," but she didn't stop living her life. She married a man she loved, and they started building a life together in southeast Georgia. However, she knew the LVAD was only a stopgap measure, and wanted to make sure she was living a full life before her health declined further. Four years after getting the LVAD, Baker started having dangerous heart rhythms. She was admitted to the Mayo Clinic in Jacksonville, Florida, and was added to the transplant list to await a new heart. For months, the 58-year-old waited, often receiving painful shocks from her LVAD and pacemaker as they tried to keep her heart functioning. Her body was also producing too many antibodies, which put her at high risk for rejecting any organs she received. Her transplant cardiologist, Dr. Pareg Patel, tested multiple medications, including chemotherapies, to reduce the antibodies. The process was "very scary," she said. One day, Patel came to her with another option: She could have a liver transplant, in addition to the new heart. It might solve the antibody problem. There was just one catch: A heart-liver transplant had never been done in someone with an LVAD before. Her other option was palliative care. "We got to talking about it, and I was like 'You're not going to know unless somebody agrees to do this. There's not much choice, really,'" Baker recalled. "It was going to be an experiment one way or the other." Sue Baker in the hospital with her caretaker, Charlene. Sue Baker A first-of-its-kind transplant The liver is "like sponges that take down these antibodies," Patel explained. Sometimes, livers are transplanted alongside hearts to lower the risk of rejection. But the procedure means a patient needs to wait until a heart and liver are available from the same donor. Some people die on the waiting list, Patel said. But for Baker, it was the best option. "It's a story where we were able to find an out-of-the-box solution for somebody who I can guarantee you two years ago we would have said no to and put them in hospice," Patel said. "She had less than probably six months to live in, more likely three months." Baker spent months in the hospital, continuing to receive painful shocks from her LVAD and pacemaker. She had other complications, including diagnoses of COVID-19 and pneumonia. In September 2024, she finally received word that a heart and liver were available to her. Sue Baker in the hospital on her birthday. Sue Baker "I was shocked," Baker said. "I was so excited." Patel said he and his team anticipated that the surgery would be "challenging" and "very high risk" because of Baker's health complications but everyone believed it was the best possible option. Baker would also be donating her "perfectly healthy" liver to another patient, Patel said, in what's known as a domino operation. "I think the cool part of this is for Sue, is that by using this technology, number one, we were able to prove that by placing a liver and a heart from somebody is we're able to make antibodies go close to zero," Patel explained. "And number two, we were able to have Sue become not only a recipient of two organs, but also a donor in the same day." Blazing a path for other patients After her surgery, Baker said she had a long recovery, but spent her time in the hospital bonding with other patients. She tried to be a voice of optimism for other people waiting for transplants, she said. She also received a letter from the person who received her liver. After Baker recovered and left the hospital in October 2024, she was eager to resume her life in Georgia, but tragedy struck: Her husband died from a sudden cardiac arrest just weeks later. Burdened by medical bills and funeral expenses, her financial situation spiraled. She said her housing is now unstable, and most spare money goes to flying to regular check-ups at the Mayo Clinic. A GoFundMe has only raised a few hundred dollars. Patel said Baker will need frequent check-ups and medication to maintain her new organs. Mayo Clinic said it offers financial assistance and payment plan options, as well as financial counseling to patients who are uninsured or underinsured. Sue Baker and her care team. (L-R) - Dr. Daniel Yip, Dr. Juan Carlos Leoni Moreno, Sue Baker, Dr. Parag Patel, Dr. Rohan Goswami. Mayo Clinic Baker said she is leaning on her church for emotional support and other aid. She has a caretaker, Charlene, who helps with day-to-day life. She also hopes that her taking part in the first-of-its-kind surgery will allow more people to receive lifesaving treatment, and said the thought brings her some solace. Patel said that another surgery like Baker's was already conducted, and that another is in the works. "If it weren't for her, these other two patients would have no opportunity," Patel said. "Doing what I did, it opened it up for so many more patients," Baker said. "It made me very happy to know that more LVAD patients will be able to go through this and actually have a long chance at life."
Yahoo
an hour ago
- Yahoo
A longer ‘winter': Public funding slowdown heightens pressure on biotech startups
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Biotechnology industry watchers were hopeful at the start of 2025. Venture funding appeared to be rebounding after a lengthy slump, and a smattering of new stock offerings and company acquisitions brewed optimism that the public markets might be similarly warming up to young drugmakers. But the positivity quickly dissipated. Trump administration policies gutted scientific research funding and raised questions about U.S. drug prices. Large layoffs and upheaval at public health agencies created regulatory turmoil that added risk to what's already, by its nature, a risky sector to invest in. The results were laid out in a June report from David Windley and Tucker Remmers, two analysts at the investment bank Jefferies. According to that report, funding in public biotech companies — be it from initial public offerings, follow-on stock offerings, or 'PIPE' deals — plummeted in May. The 'political and economic uncertainties' have "cast a cloud over biotech investment,' they wrote. 'Since product development cycles can range 12-15 years in this industry, biotechs (and their boards and investors) want clarity on FDA regulation, drug pricing, and funding before committing to large, [long-term] investments,' Windley and Remmers wrote. Investors and industry insiders interviewed by BioPharma Dive say that the public slowdown is trickling down to startups that have already been under intense pressure during a prolonged pullback. Companies and investors are struggling to align on valuations, making funding rounds more difficult to close than in prior years. The uphill battle in the public markets is further delaying IPO plans, too. "People are waiting to see what happens, and it's extended that winter," said Tim Scott, the president of Biocom California, an industry trade group. To date, only seven biotech companies have priced IPOs in 2025, and no large offerings have occurred since mid-February. No biotechs have publicly disclosed IPO ambitions in several months either, and one of the last to do so, Odyssey Therapeutics, pulled its offering in May. In a letter to the Securities and Exchange Commission, CEO Gary Glick wrote that it was 'not in the best interests of the company' to go public at that time. One reason IPOs have ground to a halt, experts say, is that the public markets aren't rewarding drug startups as predictably as they once were. Typically, drug companies can expect their value to climb after delivering positive clinical results. But 'even companies with good data aren't seeing a lot of movement in the public markets,' said Jonathan Norris, a managing director at HSBC Innovation Banking. As a result, Norris said, companies are looking at the time and expense it takes in the monthslong process to go public and wondering: 'What's the benefit?' 'If you have any readouts that are even eye squinting, you're going to get crushed,' he said. 'It's a tough, tough endeavor.' The shuttered IPO window is exacerbating problems for young biotechs. "If you don't have a public market opportunity, then the companies that are private have to think about ways to raise capital and stay private for longer," said Maina Bhaman, a partner at Sofinnova Partners. Feeling that burden, venture investors are becoming more conservative. While private funding hasn't plummeted as much as its public counterpart, investors are more selective and slower-moving. Funding has become increasingly consolidated into fewer and larger 'megarounds,' to the extent that more firms are compiling similar portfolios. And they're hard to finalize, even when most of a funding syndicate is already onboard, according to Norris. "People are struggling to figure out where the bottom of the market is and what's the appropriate valuation and expectation for that investment,' he said. "A lot of VCs are pencils down right now on deals they would otherwise be moving forward on,' Scott added. Pullbacks are nothing new in biotech. But what has been unusual, some say, is how long the sector has spent in the doldrums after peaking in early 2021. One reason is the most recent boom flooded the market with more companies than it could support. But another is that the ensuing correction has intensified amid regulatory and political upheaval. A report last week from Roel van den Akker, PwC's U.S. pharma and life science deals leader, predicted that companies will be 'preparing contingency plans' to account for delays in 'trial oversight' and drug applications. Drug companies are used to dealing with a high level of risk, as most experimental medicines never make it to market. But 'now you've got a lot more macro uncertainty that is being layered on top," Bhaman said. On the public side, that uncertainty has resulted in less patient investors, some of whom are pressing company boards to shut down after setbacks rather than change course. But some startups are taking drastic steps, too, such as cutting programs and staff to, some experts believe, depress their value so they can still attract investment. The "lack of surety" is pressuring biotechs to be as efficient as possible with their cash, Scott said, perhaps working on one program instead of a few. There have been multiple high-profile examples of late. Eikon Therapeutics and Insitro, two well-funded startups, both cited a need for 'prudence' in laying off staff. Norris expects more companies to proactively cut staff, or even close, as the longer-than-expected winter drags on. 'Most of those companies are not going to find the investors that they're hoping for,' he said. 'And I think that's just the unfortunate truth.' Recommended Reading Radiopharmaceutical drugmaker RayzeBio signals plans to go public
Yahoo
an hour ago
- Yahoo
Should You Forget Medical Properties Trust and Buy These Unstoppable Dividend Stocks Instead?
Medical Properties Trust has a 7.2% yield and a history of dividend cuts behind it. Other healthcare REITs have high yields and dividends that have withstood adversity much better. Omega Healthcare has a 7.4% yield, and LTC Properties has a 6.5% yield. 10 stocks we like better than Medical Properties Trust › Medical Properties Trust (NYSE: MPW) has a lofty 7.2% yield. That compares to the S&P 500 index's skinny little 1.2% yield, and the average real estate investment trust's (REIT's) yield of around 4.1%. On the surface, it appears to be an obvious choice. But don't jump at the chance to buy Medical Properties Trust just yet. You can get similarly large yields from healthcare REIT peers Omega Healthcare (NYSE: OHI) and LTC Properties (NYSE: LTC), and both offer a more compelling dividend story than Medical Properties. Here's what you need to know. Take a look at the chart below for Medical Properties Trust. The orange line is the quarterly dividend, and the purple line is the stock price. Notice the massive drop in both that has occurred since 2022. That was when some of the REIT's large tenants started to experience financial troubles. It was the start of a tense and complicated period when a small number of Medical Properties Trust's tenants failed, and it had no choice but to cut its dividend. For long-term dividend investors, the lofty 7.2% yield on offer from Medical Properties Trust comes with some lofty risks. It's possible that the bad news is all out, and the REIT can start to turn its business around. However, that's far from a certainty. Unless you're willing to bet that the future will look much brighter from here, most dividend investors will probably want to tread with caution. In fact, even if a turnaround is underway, it's likely to be a years-long process. There's a contrast to be made here with healthcare REITs Omega Healthcare and LTC Properties. Both of these REITs focus on senior housing, including nursing homes and assisted living facilities. During the coronavirus pandemic's height, both of these property types were hard hit. The reason was pretty simple: COVID-19 is particularly deadly for unvaccinated older adults and spreads easily in group settings. Occupancy fell for both REITs, and there was a drought of new customers. Both Omega and LTC also had to deal with tenant problems, as some of their lessees had trouble paying rent. That would seem like a perfect storm that would lead to a dividend cut. Yet neither Omega nor LTC cut their dividends. To be fair, neither of these REITs has increased their dividends in years. But a static dividend is much better than a dividend cut. Right now, Omega's yield is 7.4%, while more diversified LTC Properties has a 6.5% yield. The future is starting to look brighter for each of these healthcare REITs. Omega's adjusted funds from operations (FFO) rose year over year in the first quarter of 2025, and it increased its full-year guidance. LTC Properties, meanwhile, expects 2025's adjusted FFO per share to be flat to slightly higher. However, it's diversifying its business approach to include senior housing operating properties (SHOP). (SHOP assets are owned and operated by the REIT, though it actually hires a third party to handle day-to-day management of the asset.) As it grows, this business should increasingly benefit from the growth in demand for senior housing as the U.S. population ages. The key takeaway here, however, is that, when faced with adversity, Omega and LTC Properties held firm in their commitment to shareholders. They adjusted as needed to keep paying. Medical Properties Trust, on the other hand, couldn't manage that feat. The past doesn't predict the future, of course, but the past is all we have to go on as investors. And since all three of these healthcare REITs have faced material adversity just recently, their strengths and weaknesses have been laid bare. While the worst might be over for Medical Properties Trust, most dividend investors should probably err on the side of caution with either Omega, which has a higher yield, or LTC Properties, which has a lower yield but a far more diversified business model. Before you buy stock in Medical Properties Trust, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medical Properties Trust wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Should You Forget Medical Properties Trust and Buy These Unstoppable Dividend Stocks Instead? was originally published by The Motley Fool Sign in to access your portfolio
